Chief Business Officer
Geoffrey Swire joined Hopewell as a strategy consultant and advisor at the end of 2022. He has over 20 years of leadership experience in business, product and commercial development for life sciences companies.
Prior to joining Hopewell, Mr. Swire’s roles focused on helping development stage biotechnology companies raise capital, advance their programs and scale their capabilities toward commercialization. As Acting COO and SVP of Corporate Development at Allena Pharmaceuticals, Mr. Swire’s responsibilities spanned across external partnering efforts and internal R&D program operations. Previously, Mr. Swire supported Radius Health in completing its highly successful IPO and gaining FDA approval for its osteoporosis product, Tymlos, serving as head of business development and alliance management, and earlier as program leader for the global Phase 3 Tymlos program. Mr. Swire spent seven years at Genzyme in various leadership positions in the Transplant and Oncology business units, where he played a central role in the acquisition, development, regulatory approvals and global commercial launch of Mozobil for patients undergoing stem cell transplants. Mr. Swire started his career in strategy and product development consulting at Integral, Inc., and Accenture’s Health & Life Sciences practice.
Mr. Swire received his B.A. from Dartmouth College and his Master in Public Policy, Health Policy / Financial Markets & Analysis from Harvard University.